See the DrugPatentWatch profile for canakinumab

Based on the information available, it is difficult to provide an exact number of years for when generic versions of Canakinumab will be available. Canakinumab is a drug used to treat certain auto-inflammatory syndromes and is sold under the brand name Ilaris. The drug is manufactured by Novartis Pharmaceuticals.

According to DrugPatentWatch.com, the patent for Ilaris (Canakinumab) is set to expire in the United States in 2025 [1]. This does not necessarily mean that generic versions of the drug will become available immediately after the patent expires. The FDA approval process for generic drugs can take some time, and it is difficult to predict exactly when generic Canakinumab will become available.

It is worth noting that the patent expiration date can be subject to change, for example, if the patent holder is granted a patent extension or if the patent is challenged in court. Additionally, even after the patent expires, it may take some time for generic manufacturers to develop and gain approval for their versions of the drug.

In summary, based on the information available, generic versions of Canakinumab are expected to become available in the United States around 2025, but the exact timeline is subject to change.

Sources:
[1] <https://www.drugpatentwatch.com/drugs/canakinumab>